The success of gene therapy hinges on achievement of adequate transgene expression. To ensure high transgene expression, many gene-therapy vectors include highly active virus-derived transcriptional elements. Other vectors include tissue-specific eukaryotic transcriptional elements, intended to limit transgene expression to specific cell types, avoid toxicity and prevent immune responses. Unfortunately, tissue specificity is often accompanied by lower transgene expression. Here, we use eukaryotic (murine) transcriptional elements and a virus-derived posttranscriptional element to build cassettes designed to express a potentially therapeutic gene (interleukin (IL)-10) in large-vessel endothelial cells (ECs) at levels as high as obtained with the cytomegalovirus (CMV) immediate early promoter, while retaining EC specificity. The cassettes were tested by incorporation into helper-dependent adenoviral vectors, and transduction into bovine aortic EC in vitro and rabbit carotid EC in vivo. The murine endothelin-1 promoter showed EC specificity, but expressed only 3% as much IL-10 mRNA as CMV. Inclusion of precisely four copies of an EC-specific enhancer and a posttranscriptional regulatory element increased IL-10 expression to a level at or above the CMV promoter in vivo, while retaining-and possibly enhancing-EC specificity, as measured in vitro. The cassette reported here will likely be useful for maximizing transgene expression in large-vessel EC, while minimizing systemic effects.
INTRODUCTION
Endothelial cells (EC) of large arteries have major roles in several important physiologic and pathologic processes including regulation of hemostasis and thrombosis, control of leukocyte trafficking, regulation of vascular tone and modulation of lipoprotein entry to the vascular wall. 1 Durable, high-level expression of recombinant genes in large-vessel EC, using in vivo gene transfer, is potentially a powerful tool for understanding these biological processes and for preventing and treating human diseases, such as atherosclerosis and thrombosis. [2] [3] [4] [5] However, achievement of durable, high-level transgene expression in EC in vivo has been challenging. [6] [7] [8] [9] Several groups have focused on the problem of increasing transgene expression levels in EC while limiting expression in other cell types, in which transgene expression could be deleterious. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Expression cassettes constructed by these groups contain EC-specific eukaryotic promoter and enhancer elements, expected to be active in EC and less active in other cell types. These cassettes express transgenes at high levels in EC in tumor vessels and in small vessels of ischemic muscle, estrogen-stimulated uterine tissue, liver and lung; often with evidence of relative EC-specific expression. 11, [13] [14] [15] [17] [18] [19] [20] However, far less attention has been devoted to maximizing transgene expression in EC of large blood vessels, in which transcriptional regulation is likely different than in smaller vessels. 21 Many investigators use the cytomegalovirus (CMV) immediate early promoter to drive transgene expression in large-vessel EC despite its lack of tissue specificity and its susceptibility to attenuation and shutdown. 16, 22 The need for an EC-specific expression cassette that outperforms CMV in large-vessel EC is well enunciated; however, attempts to construct such a cassette have not been successful. 16 Several years ago, we reported that helper-dependent adenovirus (HDAd) can express a transgene in EC of large arteries for at least 2 months-far longer than first-or second-generation Ad vectorsand with negligible local inflammation. 23 These results suggest that HDAd will be extremely useful for expressing transgenes in EC of large vessels and that HDAd is therefore an attractive platform for developing and testing highly active, EC-specific expression cassettes. Here, we report use of a 1.36 kb enhancer-promoter fragment from the murine endothelin-1 (mET-1) gene, 24 a truncated version of the ET-1 enhancer-promoter that contains three additional copies of a 45-bp EC-specific ET-1 enhancer element ('ETE'), a genomic (introncontaining) DNA sequence and the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) 25 to attempt to build a cassette that expresses at least as well as CMV in large-vessel EC in vivo while retaining significant EC specificity.
reporters in experiments aimed at developing improved expression cassettes. Our initial hypotheses were that the native mET-1 enhancerpromoter would express at a lower level than the CMV promoter (as is typically the case for cell-type-specific promoters), 12, 16 and that the native mET-1 enhancer-promoter would show relative EC specificity compared with the 750-bp CMV promoter. As inclusion of introns can boost transgene expression, 16, 27 we also hypothesized that vectors containing the complete IL-10 exon-intron sequence (that is, the gDNA) would express at higher levels than vectors containing the IL-10 cDNA. We began to test these hypotheses by transducing bovine aortic EC (BAEC) with HDAd containing four different IL-10 constructs (CMV-cIL-10, CMV-gIL-10, mET1-cIL-10 and mET1-gIL-10) as well as HDAdNull, as a negative control ( Figure 1 ). We measured IL-10 mRNA in transduced cells and normalized expression both to glyceraldehyde 3-phosphate dehydrogenase mRNA and to vector DNA measured in cells from the same well. Expression from CMV-cIL-10 was 30-fold higher than mET1-cIL-10 and was approximately threefold higher than CMV-gIL-10 ( Figure 2a ). Expression from the two mET-1 vectors (mET1-cIL-10 and mET1-gIL-10) was not significantly different. Two-way analysis of variance confirmed overall effects of CMV versus mET-1 promoters (CMV4mET-1; Po0.001); this effect was present for both cDNA and gDNA. There was also an overall effect of cDNA versus gDNA (cDNA4gDNA; Po0.001); however, this was driven by the CMV results and was not evident at the low levels of expression obtained with the mET1 promoter.
We next looked for evidence of EC specificity of the mET-1 enhancer-promoter. The same vectors were used to transduce bovine aortic smooth muscle cells (BASMCs), and IL-10 expression was again measured. For both BAEC and BASMC, IL-10 expression from the CMV promoter-containing vectors (both cDNA and genomic) was assigned a value of 100%. Expression from each of the mET-1containing vectors was then calculated as a fraction of the expression of the analogous CMV-containing vector in the same cell type. Using this calculation, EC specificity would manifest as a higher percentage of CMV-mediated expression in EC than in SMC. The mET1-gIL-10 cassette expressed IL-10 mRNA at a higher relative level in BAEC than BASMC (fourfold higher; P¼0.009) whereas the mET1-cIL-10 cassette expressed at a similar level relative to CMV in both cell types ( Figure 2b ; P¼0.6). Two-way analysis of variance confirmed an overall effect of cell type (EC4SMC) on level of transgene expression from the mET-1 promoter (P¼0.03).
We next performed this same four-vector comparison in our in vivo EC gene transfer model. 9, 28 The four IL-10-expressing vectors and the control vector HDAdNull were infused into surgically isolated rabbit carotid arteries and IL-10 mRNA was measured in arterial extracts 3 days later. In contrast to the in vitro results, expression from HDAd-CMV-gIL-10 was highest in vivo (twofold above HDAd-CMV-cIL-10; P¼0.06; Figure 2c ). Similar to the in vitro results, IL-10 mRNA levels in arteries infused with either of the mET-1 vectors were far below IL-10 mRNA levels in arteries infused with the CMV vectors. The background signal in this experiment was the quantitative real-time PCR signal from arteries transduced with HDAdNull; the signal from arteries transduced with both of the mET-1 vectors was at this level ( Figure 2c ). Therefore, if either of the mET-1 vectors expressed IL-10 mRNA in vivo, the level of mRNA was too low for us to detect.
Increased IL-10 expression and preserved EC specificity in vitro after addition of EC-specific enhancer elements To increase expression from the mET-1 promoter, we constructed plasmids in which the ET-1 promoter sequence 5¢ of the native 45-bp EC-specific ET-1 enhancer (the ETE; located at À364 to À319 in the mouse ET-1 gene; Figure 1) 24 was replaced by two, three or four additional copies of the ETE. In these plasmids, the ETE were located upstream of a minimal (318 bp) mET-1 promoter and the rabbit IL-10 cDNA ( Supplementary Figure 1) . These plasmids were transfected into BAEC and expression of IL-10 mRNA quantified. The plasmid containing three copies of the ETE (the native ETE with two additional copies: '3XETE') expressed 4-5-fold more IL-10 mRNA than the plasmid containing one ETE copy. The plasmid with four copies of the ETE ('4XETE') expressed twice as much IL-10 mRNA as plasmids containing three or five copies (Po0.001 for all comparisons; Figure 3a ). Figure 1 Expression cassettes. Cassettes were tested both in plasmid vectors in vitro and in HDAd in vitro and in vivo. Symbols: CMV, CMV promoter from pCI plasmid; i, b-globin/IgG chimeric intron from pCI; MCS, multiple cloning site; pA, SV40 poly A signal; 5U, 5¢-untranslated region of rabbit IL-10 gene; 1, 2, 3, 4, 5 (yellow blocks), rabbit IL-10 exons; 3U, 3¢-untranslated region of rabbit IL-10 gene; mET-1, native murine endothelin-1 enhancer-promoter; red arrows, ET-1 enhancer (ETE) in native position and with three additional ETE added as direct repeats (4XETE); ET-1 EX-A and ET-1 EX-B, 5¢ and 3¢ segments of mouse ET-1 exon 1 (untranslated); ET-1 intron, 5¢ segment of mouse ET-1 intron 1; oPRE, optimized woodchuck hepatitis virus PRE. Drawing is not to scale.
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On the basis of this result, we constructed a new HDAd in which three copies of the ETE were added upstream of the endogenous ETE and minimal mET-1 promoter (4XETE-cIL-10; Figure 1 ). EC were transduced with one of three HDAd: 4XETE-cIL-10, CMV-cIL-10 or mET1-cIL-10 and IL-10 mRNA measured. In these experiments, in relation to CMV-cIL-10 expression set at 100%, inclusion of four ETE copies increased IL-10 expression by about sevenfold compared with HDAd-mET1-cIL-10 ( Figure 3b ; Po0.001). However, this increased level of expression was still only about 30% of levels obtained with HDAd-CMV-cIL-10 (P¼0.02).
To determine whether addition of three copies of the ETE and removal of the ET-1 promoter sequences 5¢ of the native ETE (in HDAd4XETE-cIL-10) affected EC specificity, we compared IL-10 expression from HDAd4XETE-cIL-10 in BAEC and BASMC. When normalized to CMV-directed expression in the same cell type, HDAd4XETE-cIL-10 expressed approximately fourfold more IL-10 mRNA in BAEC than in BASMC (Po0.001; Figure 3c ). By comparing these data to data generated with the mET1-driven vectors (Figure 2b ), we noted that addition of the 4XETE increased IL-10 expression not only in EC, but also in SMC. Therefore, the 4XETE is not completely EC specific. To assess this observation more quantitatively, we repeated the measurements of IL-10 expression using a randomly selected subset of samples from the in vitro experiments with the mET1-cIL10 and 4XETE-cIL-10 vectors (samples from the experiments shown in Figures 2b and 3c ). We measured IL-10 expression simultaneously in all samples, without normalization to CMV expression in the same cell type ( Figure 4 ). These measurements revealed-as in Figure 2b -that expression from mET1 was low in both EC and SMC. However, here we detected significantly higher expression from mET1 in EC versus SMC (twofold; Po0.001). Addition of the 4XETE increased IL-10 expression in both cell types but far more in EC than SMC (280-fold versus 28-fold). Therefore, although the 4XETE is not completely EC specific, it is far more active in EC than SMC and therefore contributes both higher expression and increased EC specificity above that achieved with the mET1 promoter.
Increased IL-10 expression and preserved EC specificity in vitro after addition of a PRE To further increase vector-mediated transgene expression while hopefully maintaining relative EC specificity, we inserted both the WPRE 25 and an optimized version of this element (oPRE; in which the potentially oncogenic X protein sequences are deleted) 29 into the IL-10 3¢ UTR in plasmids containing the CMV-cIL-10 and 4XETE-cIL-10 expression cassettes. We tested both PRE in both orientations in plasmids containing both the CMV and 4XETE-mET-1 promoters. Results of these EC transfections were generally unimpressive, with increased IL-10 mRNA (less than twofold) only from the WPRE in the forward orientation, and only with the CMV promoter ( Supplementary Figures 2a and b ).
As our in vitro plasmid transfection data did not always predict relative expression levels when the same cassettes were transduced by HDAd in vivo (compare CMVcIL-10 and CMVgIL-10 in Figure 2a versus c), before abandoning the PREs we tested one of them in an HDAd. We selected the oPRE in the forward orientation, and used it to construct HDAd4XETE-cIL-10-oPRE ( Figure 1 ). In this experiment, in relation to CMV-cIL-10 expression set at 100%, BAEC transduced with HDAd4XETE-cIL-10-oPRE expressed about 50% more IL-10 mRNA than BAEC transduced with HDAd4XETE-cIL-10 ( Figure 5a ; P¼0.01). This level of expression was about 60% of that obtained in parallel transductions with HDAd-CMV-cIL-10. At this stage of our experiments, we developed a western blot method for detection of rabbit IL-10 protein. Western analysis of media conditioned To determine whether addition of the oPRE affected EC specificity, we compared IL-10 expression from HDAd4XETE-cIL-10-oPRE in BAEC and BASMC. When normalized to CMV-directed expression in the same cell type, HDAd4XETE-cIL-10-oPRE expressed approximately threefold more IL-10 mRNA in BAEC than in BASMC (Po0.001; Figure 5b ). Therefore, significant EC specificity was retained after addition of the oPRE. To further examine the potency and specificity of the oPRE, we measured IL-10 mRNA in a randomly selected subset of samples from those portrayed in Figure 5b , and compared IL-10 mRNA in these samples with IL-10 mRNA in samples from EC and SMC transduced with the mET1-cIL-10 and 4XETE-cIL-10 vectors (Figure 4 ). This analysis revealed that addition of the oPRE increased IL-10 expression equally (threefold) in both cell types. Therefore, unlike the 4XETE, the oPRE does not act preferentially in EC.
Increased in vivo IL-10 expression from vectors containing 4XETE and the oPRE We next tested whether addition of the 4XETE and oPRE to the mET-1 promoter also increased transgene expression in rabbit EC in vivo. IL-10 mRNA was measured in rabbit carotids infused with one of four HDAd: CMV-cIL-10, mET1-cIL-10, 4XETE-cIL-10 and 4XETE-cIL-10-oPRE ( Figure 6 ). As before, expression from mET1-cIL-10 was far below expression from CMV-cIL-10. Addition of the three ETE copies to the native mET-1 enhancer-promoter greatly increased IL-10 expression (ninefold; Po0.001), yielding expression that was not significantly different from that obtained with the CMV promoter-containing vector (P¼1). Addition of the oPRE further increased IL-10 expression by twofold (P¼0.01 versus Figure 3 Enhancement of IL-10 expression and preservation of EC specificity after addition of ET-1 enhancer (ETE) sequences to the mET-1 promoter. (a) EC were transfected with plasmids containing the 318 bp mET-1 promoter, the IL-10 cDNA, and 1, 3, 4 or 5 copies of the ETE (see Supplementary Figure 1 ). IL-10 mRNA was measured by quantitative realtime (qRT)-PCR. Mean IL-10 expression for the 1XETE construct was assigned a value of 100%. Expression measured in individual wells was calculated as a percentage of this value and represented here as mean ± s.d. (b) EC were transduced with HDAd containing the indicated expression cassettes (see Figure 1 ) and IL-10 mRNA measured by qRT-PCR. Mean IL-10 expression for the CMV-cIL-10 group was assigned a value of 100%. Values from individual wells are expressed as a percentage of this value. Bars are group means. (c) EC or SMC were transduced with HDAd containing the CMV-cIL-10 or the 4XETE-cIL-10 cassettes (Figure 1) and IL-10 mRNA measured by qRT-PCR. For each cell type, mean IL-10 expression for the CMV-cIL-10 group was assigned a value of 100%. IL-10 expression from individual wells is expressed as a percentage of this value. Bars are group means; s.d. are shown in a. Figure 4 Relative activities of the 4XETE and oPRE in EC and SMC. Bovine EC or SMC were transduced with HDAd in which expression of the IL-10 cDNA is driven by the mET1 enhancer-promoter, the truncated mET1 enhancerpromoter with three additional copies of the ETE (4XETE), or the 4XETE enhancer-promoter with the oPRE added (see Figure 1 ). IL-10 mRNA was measured by quantitative real-time (qRT)-PCR, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA in the same extracts, and expressed as arbitrary units (AU). Background signal in this assay was determined by measurement of IL-10 mRNA in extracts of EC and SMC transduced with HDAdNull. Data points are from individual wells, bars are group means. The cell extracts assayed here are a subset of those represented in Figures 2b, 3c and 5b. We repeated our measurements of IL-10 and GAPDH mRNA in these three sets of extracts (qRT-PCR was performed on all three sets simultaneously here) to generate data for this figure.
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Lack of systemic vector dissemination and transgene expression
If vectors are released from the site of infusion, disseminate throughout the animal, and transduce cells in distant tissues, and if the transduced cells in these distant tissues are not EC, then transgene expression in distant tissues could provide an in vivo read-out of promoter specificity. We therefore determined whether vector DNA was present in distant tissues after carotid gene transfer, and if so whether the IL-10 transgene was expressed.
We measured vector DNA and IL-10 expression in tissues from rabbits after carotid artery infusion of either HDAd-CMV-cIL-10 or HDAdNull. Vector DNA was below background levels (as determined by measurement of DNA in tissues of unoperated animals) in all tissues other than the carotids (Figure 7a ). As vector-directed RNA (present as numerous copies per cell) might be more easily detected than vector DNA (fewer copies per cell), we also measured IL-10 mRNA in these organs. IL-10 mRNA was not significantly above background levels (as determined by measurement of IL-10 mRNA in tissues from HDAdNull-infused rabbits) at any site other than the common carotid artery (Figure 7b ).
DISCUSSION
The objective of this study was to construct an expression cassette that would drive high-level transgene expression in large-vessel EC transduced by an HDAd vector and also provide significant cell-type specificity. The need for an EC-specific cassette that achieves expression levels in large-vessel EC at least as high as those obtained with the CMV promoter is well stated in a recent article by White et al. 16 We pursued this goal using rabbit IL-10 cDNA and genomic clones, murine ET-1 promoter and enhancer sequences, and a PRE. Our major findings were: (1) the native murine 1.36 kb ET-1 enhancerpromoter expresses at a far lower level than the CMV promoter in EC both in vitro and in vivo.
(2) Inclusion of rabbit IL-10 introns in the expression cassette leads to a modest increase in IL-10 expression in rabbit EC in vivo, but lowers expression in BAEC in vitro. (3) The 1.36 kb native murine ET-1 enhancer-promoter provides modest EC specificity of transgene expression. (4) Addition of ET-1 enhancer elements substantially increases transgene expression in EC both in vitro and in vivo and increases EC specificity. (5) Addition of a PRE further increases transgene expression in EC. (6) Transgene expression from a cassette including a 364-bp ET-1 enhancerpromoter, three additional ET-1 enhancers and a PRE is at least as high as is obtained with the CMV promoter in vivo, and-based on parallel in vitro studies-is more EC specific.
The CMV promoter is often incorporated into gene-transfer vectors because of its high activity, small size and ability to express transgenes in a wide range of cell types. CMV is especially useful for proof-ofconcept studies that require only a burst of transgene expression, especially those carried out only in vitro. However, the utility of CMV in vivo is limited by its lack of tissue specificity, which allows transgene expression in nontargeted cell types including antigen-presenting cells. 22, 30 The CMV promoter is also susceptible to promoter attenuation and shutdown, far more so than eukaryotic promoters. 22, 31 Other disadvantages of CMV for cardiovascular applications include downregulation by b-blockers 32 (drugs that are taken by many patients with cardiovascular diseases) and upregulation by inflammation, 23 which many cardiovascular therapies aim to reduce. 33 
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As a result of the limitations of CMV and other viral promoters for EC-targeted gene transfer, several groups have constructed and tested vectors with putative EC-specific promoters including Flt-1, ICAM-1, ICAM-2, von Willebrand factor, Tie-1, Tie-2, flk-1, vascular endothelial cadherin, lysyl oxidase-1 and endoglin. [11] [12] [13] [14] [15] [16] In several cases relative EC specificity was achieved compared with viral or broadly active eukaryotic promoters such as phosphoglycerate kinase. However, EC specificity was acquired at the cost of reliably lower transgene expression. 12, 14, 16 In work published largely since we began this project, the ET-1 promoter and enhancer were used to target EC-with apparent success-by at least two groups. One group used the ET-1 promoter and a multimerized 3XETE to construct Ad for use in EC-targeted gene therapy aimed at blocking tumor angiogenesis or promoting ischemic angiogenesis. 17, 18, 20, 34 The vectors appeared relatively EC-specific and dramatically outperformed the CMV promoter both in vitro (in BAEC and human umbilical vein endothelial cells) and in vivo. However, the exact sequences of these ET-1-based promoterenhancer constructs are not published, 17, 18, 20, 34 and the in vivo expression data are largely limited to small vessels, with no quantitation of absolute expression levels achieved in large-vessel endothelium. 17, 18, 34 For these reasons it is difficult to compare our results with these precedents. A second group fused multimers of the ETE (4X and 7X) to the human Cdc6 and cyclin A promoters, to generate expression cassettes specific for proliferating EC. 19, 35 The ETE multimers added EC specificity to these proliferation-sensitive promoters and conferred on the Cdc6 promoter an ability to express a reporter gene in tumors and estrogen-stimulated uterus at a level similar to that obtained with the CMV promoter. However, these expression levels appeared low; only about 1% of CMV expression in normal lung. Our study is the first to introduce a eukaryotic expression cassette in vivo in large-vessel EC and unequivocally achieve transgene expression at least as high as obtained from the CMV promoter.
Several groups have shown that inclusion of introns in plasmid and viral vectors increase transgene expression. 16, 27, 30, 36, 37 We were therefore surprised that the IL-10 cDNA vector expressed significantly more IL-10 mRNA in vitro than the genomic IL-10 vector (Figure 2a ). In contrast, the genomic vector expressed more IL-10 mRNA than the cDNA vector in vivo (Figure 2c ). The reason for this discrepancy is unclear, but could include use of EC from different species (bovine in vitro versus rabbit in vivo) or alteration in EC transcriptional regulation after removal from the vessel wall. 21 It is possible that bovine-but not rabbit-EC express a transcriptional regulator that suppresses expression by binding to the genomic rabbit IL-10 sequences. We could not test the role of species specificity because rabbit ECs are no longer available to us. Another example of in vitro/ in vivo discrepancy is evident in Figures 5a and 6 , in which the 4XETE-oPRE vector compares far more favorably to CMV in vivo than in vitro. This might be due to presence of ETE-binding transcription activators in rabbit EC in vivo versus their absence in cultured BAEC. As we constructed the final two vectors (4XETE-cIL-10 and 4XETE-cIL-10-oPRE; Figure 1 ) based on in vitro results showing superiority of the IL-10 cDNA (Figure 2a ), we may have missed an opportunity to construct vectors that-because they contained the genomic IL-10 sequence-expressed higher than both 4XETE-cIL-10-oPRE and CMV-cIL-10 in vivo ( Figure 6 ). However, the increased expression level provided by the genomic DNA versus cDNA was relatively small (twofold; Figure 2c ), of only borderline significance (P¼0.06) and was not found in transduced arteries of fat-fed rabbits (data not shown). On the basis of the comparatively dramatic effect of adding three copies of the ETE (4200-fold increase; Figure 4 ) introduction of additional 5¢ regulatory elements to the expression cassette is likely to be a more fruitful approach for increasing transgene expression.
Some of the features of the rabbit carotid model used here are worthy of comment. First, compared with the rat carotid gene transfer model with which we investigated transcriptional regulation in EC, 38 gene transfer in the rabbit model is more reproducible and transgene expression levels are farther above background. Second, there is no evidence in the rabbit model of vector dissemination beyond the site of gene transfer (Figure 7) . Although it is likely that a small amount of vector is released systemically and is present in distant tissues below the limit of assay detection, our data nevertheless suggest that surgically isolated blood vessels can be efficiently transduced in situ by Ad without causing a potentially toxic systemic exposure to Ad. 39 In summary, we report an animal model and a general approach (incorporation of EC-specific transcriptional elements and other cis-acting sequences) that dramatically increases HDAd-driven transgene expression in EC ( Figure 6 ). In vivo expression levels with the final construct are at least as high as those obtained with CMV. To our knowledge expression from a eukaryotic-based promoter at a level equivalent to CMV has never been unequivocally demonstrated in EC of a large vessel. Moreover, in vitro studies (Figures 4 and 5b) provide strong support for preservation of substantial EC specificity, even at the highest expression levels. This model and approach will be useful for testing additional vector modifications aimed at further increasing transgene expression, 30, 40 adding physiologic regulation 41 and enhancing duration of expression. Improved vectors designed and tested with this approach, will increase the likelihood that vascular gene therapy will be clinically useful.
MATERIALS AND METHODS

Construction of IL-10 expression cassettes and HDAd vectors
A plasmid containing a rabbit IL-10 cDNA was a kind gift from Dr Harvey Perkins (Australian National University, Canberra, Australia). 42 We cloned the rabbit IL-10 gene by PCR amplification of genomic DNA extracted from the skin of a New Zealand White rabbit. Plasmid pqET-1, containing the mET-1 promoter, was obtained from Dr T Quertermous (Stanford University, Palo Alto, CA, USA). To increase expression from cassettes containing the mET-1 promoter, we inserted additional copies of a 45-bp endothelium-specific enhancer element ('ETE') 24 present in the mET-1 promoter upstream of the native ETE in the mET-1 promoter. Multimers of the ETE were constructed using standard recombinant DNA methods. The WPRE was obtained from Dr David Russell (University of Washington, Seattle, WA, USA). 43 We also used a truncated version of the WPRE, termed 'oPRE' or 'optimal PRE' , obtained from Dr Axel Schambach (Hannover Medical School, Germany). 29 The oPRE lacks the X protein-coding sequence and promoter, which are associated with oncogenic activity. 44 To enable efficient transfer of the IL-10 expression cassettes into the HDAd backbone plasmid pC4HSU (Microbix Biosystems, Toronto, ON, Canada) we constructed a shuttle plasmid that we used to insert cloned sequences into pC4HSU by homologous recombination (Supplementary Figure 4) . A detailed description of cloning of the rabbit IL-10 gene, construction of all of the expression cassettes (Figure 1) , as well as generation and production of the HDAd vectors is provided in the Supplementary Information.
Characterization of HDAd vectors
Viral particle (part) concentration was measured by spectrophotometer and was typically 1-3Â10 2 part ml -1 (Mittereder et al. 45 ). E1A and helper virus (H14) contamination were measured with a quantitative (q) PCR-based approach in which viral genomes were measured by qPCR for SV40 polyA sequences and both E1A containing and H14 sequences were measured by qPCR for sequences present only in E1A or H14. Absolute quantification of copies was achieved by reference to standard curves constructed by performing qPCR on known amounts of plasmid DNA containing the target sequences. Probes for qPCR were from Applied Biosystems (Foster City, CA, USA) or IDT (Coralville, IA, USA), primers were from Invitrogen (Carlsbad, CA, USA) or Bioneer (Alameda, CA, USA), and qPCR reagents were from Abgene/Thermo Fisher (Waltham, MA, USA). E1A contamination in the viral preparations was below 1 in 10 6 HDAd genomes, and helper virus contamination was less than 1% of HDAd genomes.
Quantification of IL-10 expression in vitro
BAECs and BASMCs were purchased (Cell Applications Inc., San Diego, CA, USA) and expanded in culture. Cells were transduced at passages 6-8 by addition of HDAd at 1Â10 10 part ml -1 (multiplicity of infection approximately 2Â10 4 ) at t¼0. After 6 h, the vector-containing medium was aspirated, and the cells washed and incubated with fresh medium. The cells were harvested at t¼24 h. RNA was extracted and purified using Trizol (Invitrogen) or the RNeasy mini kit (Qiagen, Valencia, CA, USA); DNA was extracted and purified with the DNeasy kit (Qiagen). RNA was first digested with DNase I to remove contaminating genomic DNA, then 100 ng of RNA was reverse-transcribed and amplified with a one-step quantitative real-time PCR protocol and reagents from Abgene/Thermo Fisher. Quantitative real-time PCR probes were from Applied Biosystems or IDT and the primers from Bioneer. The IL-10-specific sequences are: forward primer, 5¢-AGAACAGCTGCATTCACTTTCCA-3¢; reverse primer, 5¢-CCTTCGATTGAAAGAAAGTCTTCAC-3¢; probe, 5¢-6-FAM-CTCCGCGAGCTCCGTGCTGC-TAMRA-3¢. Cycle threshold (Ct) values for IL-10 were normalized for the amount of input RNA using Ct values for glyceraldehyde 3-phosphate dehydrogenase obtained with the same RNA sample. IL-10/glyceraldehyde 3-phosphate dehydrogenase values were then normalized for transfection/transduction efficiency by dividing by the number of vector copies in the transfected/transduced cells, obtained by qPCR for the SV40 polyA sequence. In each set of experiments, IL-10 expression from a CMV promoter-containing vector (containing the IL-10 cDNA for all experiments except for the cell-type-specificity experiments, in which both the cDNA and genomic DNA-containing vectors were used) was assigned a value of 100%. Expression from mET-1 promoter-containing vectors was calculated as percentage of the expression of the analogous CMV promoter-containing vector, measured in the same cell type. All in vitro experiments were performed three times with an n¼3 per treatment each time. All data points (n¼9) were pooled for final analyses.
In vivo gene transfer
Specific pathogen-free male New Zealand White rabbits (3-4 kg, Western Oregon Rabbit Co., Philomath, OR, USA) were fed a normal chow diet. After at least 1 week of adaption to new housing, rabbits underwent bilateral gene transfer to their common carotid arteries. This procedure, carried out under general anesthesia, includes surgical isolation and vector infusion into the lumens of isolated carotid segments for 20 min, and achieves gene transfer almost exclusively to luminal ECs. 9, 28 All animal protocols were approved by the Office of Animal Welfare of the University of Washington.
Quantification of vector copies and IL-10 expression in vivo
Carotid arteries were harvested 3 days after gene transfer and cut into four equal segments designated A, B, C and D from the proximal to distal end. To measure HDAd vector copy number, DNA was isolated from both segment B and segment D, using the DNeasy Blood and Tissue kit (Qiagen). Segments A and C were snap frozen in liquid nitrogen for later extraction of RNA with the RNeasy mini kit (Qiagen).
To evaluate whether this carotid gene transfer protocol resulted in vector dissemination and ectopic expression, in some rabbits we harvested RNA and DNA from several organs (brain, heart, lung, liver, spleen, kidney, muscle and intestine) at the same time the carotids were harvested. RNA and DNA from these tissues were extracted as described above.
Western analysis of IL-10
BAEC were transduced with 1Â10 10 part ml -1 of HDAdNull, HDAd-CMV-cIL-10 or HDAd-4XETE-cIL-10-oPRE for 6 h. Medium was changed to Dulbecco's modified Eagle's medium and collected after 24 h. Vector DNA isolated from the cells and quantified by qPCR revealed equivalent transduction in all three groups (data not shown). Equal volumes of conditioned medium were resolved under reducing conditions by electrophoresis on 0.1% sodium dodecyl sulfate 15% polyacrylamide gels. Proteins were transferred electrophoretically to an immobilon-P membrane (Millipore, Billerica, MA, USA). After blocking in 10 mM Tris-HCl buffer, pH 8.0, containing 150 mM sodium chloride, 0.1% Tween 20 and 5% (w/v) nonfat dry milk, IL-10 protein was detected with goat anti-human IL-10 primary antibodies (R&D Systems, Minneapolis, MN, USA) followed by incubation with horseradish peroxidase -conjugated donkey Endothelial cell expression cassette N Dronadula et al
